VRE, or vancomycin-resistant enterococci, is a type of bacteria that has developed resistance to the antibiotic vancomycin, making it a significant concern in healthcare settings. It can cause a range of infections, particularly in patients with weakened immune systems. VRE is important to monitor due to its implications for treatment options and infection control.
Sorted into three lenses: who is speaking, what is being said about them, and where they are aligned or in conflict.
Claims about this entity's actions, status, or capabilities.
Subject
Quote from Video
The first reports of Vancomycin resistant bacteria emerged in France in 1986. Not with Staph but another pesky bug called Enterococcus faecium: Vancomycin-resistant enterococci or VRE.
“The first reports of Vancomycin resistant bacteria emerged in France in 1986. Not with Staph but another pesky bug called Enterococcus faecium: Vancomycin-resistant enterococci or VRE.”
Subject
Quote from Video
The first reports of Vancomycin resistant bacteria emerged in France in 1986. Not with Staph but another pesky bug called Enterococcus faecium: Vancomycin-resistant enterococci or VRE.
“The first reports of Vancomycin resistant bacteria emerged in France in 1986. Not with Staph but another pesky bug called Enterococcus faecium: Vancomycin-resistant enterococci or VRE.”